EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries

Rebecca Calthorpe, Margaret Rosenfeld, Christopher H Goss, Nicole Green, Mark Derleth, Siobhán B Carr, Alan Smyth, Iain Stewart

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2024.01.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Rebecca Calthorpe und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Nottingham, Nottingham, UK; NIHR Nottingham Biomedical Research Centre, Nottingham, UK. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Registries, Enzyme Replacement Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Relieving gastrointestinal symptoms is a research priority in cystic fibrosis. Emerging evidence highlights effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on gastrointestinal function, including pancreatic sufficiency. This study explores ivacaftor licensing and treatment on recorded pancreatic enzyme replacement therapy (PERT) prescription in the US and UK CF registries. METHODS: Retrospective longitudinal registry study of recorded pancreatic PERT use between 2008 and 2017. Interrupted time series analysis in propensity-matched cohorts estimated annual change and step change according to ivacaftor eligibility before and after licensing year, 2012. Generalised estimating equations assessed adjusted risk of PERT use in individuals treated with ivacaftor after 2012 compared to untreated individuals. RESULTS: In the US CF registry, the difference in annual change in prevalence of PERT use post-2012 between eligible cases and ineligible controls was -5.0 per 1000 people/year (95 %CI -7.6; -2.3, p = 0.001). The step change and annual change in prevalence of PERT use in eligible cases was not significantly different to controls in the UK CF registry. Relative to the relationship in 2013, ivacaftor treatment in the US CF registry was associated with a lower adjusted risk ratio of PERT use compared to untreated individuals by 2016 (0.97, 95 %CI 0.96; 0.99), which was not observed in the UK CF registry. CONCLUSIONS: Licensing of ivacaftor was followed by a lower prevalence of PERT use in the eligible US population compared to pre-licensing period, as well as lower risk of PERT use in those who received treatment. Inconsistencies in US and UK CF registries were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsRegistriesEnzyme Replacement TherapyQuinolonesChloride Channel AgonistsHumansUnited KingdomUnited StatesMaleFemaleRetrospective StudiesAdultLongitudinal StudiesAdolescentExocrine Pancreatic InsufficiencyChildCystic Fibrosis Transmembrane Conductance Regulator

Stichwörter der Autor:innen

Cystic fibrosisGastrointestinalIvacaftorPERTPancreasPrevalenceRegistry

Substanzen

ivacaftorAminophenolsQuinolonesChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance Regulator

Autor:innen und Institutionen

  • School of Medicine, University of Nottingham, Nottingham, UK; NIHR Nottingham Biomedical Research Centre, Nottingham, UK.
  • Seattle Children's Research Institute and Department of Pediatrics, University of Washington School of Medicine, US.
  • Seattle Children's Research Institute and Department of Pediatrics, University of Washington School of Medicine, US; Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington School of Medicine,…
  • Seattle Children's Research Institute and Department of Pediatrics, University of Washington School of Medicine, US; Division of Gastroenterology, University of Washington School of Medicine, US.
  • Division of Gastroenterology, University of Washington School of Medicine, US.
  • National Heart and Lung Institute, NIHR Imperial Biomedical Research Centre, Imperial College, London, UK; Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, part of GSTT NHS Foundation Trust, Londo…

Förderung

  • NIDDK NIH HHS
  • NIHR

Zitieren

APA

Calthorpe, R., Rosenfeld, M., Goss, C. H., Green, N., Derleth, M., Carr, S. B., Smyth, A., & Stewart, I. (2024). Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.01.011

Vancouver

Calthorpe R, Rosenfeld M, Goss CH, Green N, Derleth M, Carr SB, et al. Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.01.011

BibTeX
@article{Calthorpe2024,
  author = {Calthorpe, Rebecca and Rosenfeld, Margaret and Goss, Christopher H and Green, Nicole and Derleth, Mark and Carr, Siobhán B and Smyth, Alan and Stewart, Iain},
  title = {Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2024.01.011}
}
Kostenlos starten →